Ask AI

InterACT Oncology Team Training: Integrating Bispecific Antibodies Into Patient-Centered Management of DLBCL—Enhancing the Patient–Provider Therapeutic Connection

Enhance your clinical decision-making for DLBCL to ensure that treatment strategies reflect the most recent evidence and personalize patient outcomes through a certified on-demand webcast with accompanying downloadable slides and an expert-written ClinicalThought commentary.

Share

Program Content

Activities

BsAbs for DLBCL
InterACT Oncology Team Training: Integrating Bispecific Antibodies Into Patient-Centered Management of DLBCL—Enhancing the Patient–Provider Therapeutic Connection
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 11, 2026

Activities

Bispecific Antibodies for Management of DLBCL
InterACT Oncology Team Training: Integrating Bispecific Antibodies Into Patient-Centered Management of DLBCL—Enhancing the Patient–Provider Therapeutic Connection
Video
Congratulations: You achieved a completion on 04/09/2022

Released: April 22, 2026

Expires: October 21, 2026

Activities

Bispecifics in DLBCL
Our Thoughts on Recognizing and Managing Adverse Events Associated With Bispecific Antibodies in the Management of Patients With DLBCL
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: May 07, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education, in partnership with Smart Patients, Inc.

Supporters

Supported by an educational grant from Genentech, a member of the Roche Group.

Genentech, a member of the Roche Group

Partners

Smart Patients, Inc.

ProCE Banner